Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
第2相
実施中(募集終了)
NCT02883062
| 対象疾患 | Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma |
|---|
| 相 | 第2相 |
|---|
| スポンサー | National Cancer Institute (NCI) |
|---|
| ステータス | 実施中(募集終了) |
|---|
| 参加者数 | 67 名 |
|---|
| 介入(薬剤) | Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy |
|---|
| 開始日 | 2017年8月2日 |
|---|
| 完了日 | 2019年12月18日 |
|---|
| 結果公開日 | 2024年6月18日 |
|---|
概要
This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Change in Tumor Infiltrating Lymphocyte (TIL) Percentage
Baseline and between days 18-22 following completion of cycle 1 (each cycle is 3 weeks) · percentage of TIL
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 16.7 percentage of TIL |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 17.5 percentage of TIL |
|---|
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 18.3 percentage of TIL |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 21.7 percentage of TIL |
|---|
Pathologic Complete Response (pCR) Rate
At the time of surgery (3-6 weeks after last dose of neoadjuvant chemotherapy, neoadjuvant chemotherapy will be up to 12 weeks in length) · Participants
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 3 Participants |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 25 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。